Sedative‑Hypnotics: Barbiturates and Z‑drugs

Introduction / Overview

Barbiturates and Z‑drugs represent two distinct classes of sedative‑hypnotics that have been widely employed to manage insomnia, anxiety, and seizure disorders. Their therapeutic utility derives from an ability to modulate central nervous system (CNS) excitability, primarily through interaction with the γ‑aminobutyric acid type A (GABA_A) neurotransmitter system. Contemporary practice increasingly favors Z‑drugs owing to their more favorable side‑effect profile, yet barbiturates retain a niche role in refractory seizure management and certain anesthetic protocols. A comprehensive understanding of their pharmacodynamic and pharmacokinetic properties is essential for safe prescribing, particularly in vulnerable populations such as the elderly, pregnant patients, and those with hepatic or renal impairment.

Learning objectives

• Describe the chemical and pharmacological classification of barbiturates and Z‑drugs.
• Explain the mechanisms by which these agents influence GABA_A receptor activity.
• Summarize the key pharmacokinetic parameters that guide dosing and monitoring.
• Identify common therapeutic indications and off‑label uses.
• Recognize major adverse effects, drug interactions, and special‑population considerations.

Classification

Barbiturates

Barbiturates are heterocyclic compounds derived from barbituric acid. They are traditionally classified according to their pharmacokinetic profile: short‑acting (e.g., phenobarbital, secobarbital), intermediate‑acting (e.g., amobarbital), and long‑acting (e.g., thiopental, pentobarbital). Chemical modifications at the 5‑position influence lipid solubility and, consequently, onset and duration of action. The most frequently encountered barbiturates in clinical practice include phenobarbital, secobarbital, and thiopental.

Z‑drugs

Z‑drugs, also known as non‑benzodiazepine hypnotics, are structurally distinct from benzodiazepines but share a common pharmacologic target: the benzodiazepine binding site of the GABA_A receptor. The principal agents—zolpidem, zaleplon, and eszopiclone—are classified according to their selectivity for receptor subunits. Zolpidem and eszopiclone preferentially bind α1 subunits, conferring hypnotic potency, whereas zaleplon has a higher affinity for α3 subunits, contributing to anxiolytic effects.

Mechanism of Action

Barbiturates

Barbiturates act as non‑competitive agonists at the GABA_A receptor. Binding at the transmembrane domain increases the duration of chloride channel opening, thereby enhancing GABA‑mediated hyperpolarization. This effect reduces neuronal firing and promotes CNS depression. Additionally, barbiturates possess a secondary mechanism whereby high concentrations inhibit voltage‑gated sodium channels, contributing to anticonvulsant activity. The overall effect is a dose‑dependent CNS depressant that can transition from sedation to anesthesia and, at supratherapeutic levels, respiratory depression.

Z‑drugs

Z‑drugs bind selectively to the benzodiazepine site of the GABA_A receptor, acting as positive allosteric modulators. Their binding enhances GABA affinity and increases the frequency of chloride channel opening, producing a net hyperpolarizing effect. The selectivity for specific α subunits accounts for the distinct pharmacologic profiles: α1 subunit engagement yields hypnotic effects; α3 subunit engagement correlates with anxiolysis and muscle relaxation. Unlike barbiturates, Z‑drugs lack significant activity at voltage‑gated sodium channels, resulting in a lower risk of respiratory depression at therapeutic doses.

Pharmacokinetics

Absorption

Both barbiturates and Z‑drugs are orally administered and absorbed rapidly from the gastrointestinal tract. Bioavailability varies: phenobarbital achieves ~100% absorption, whereas eszopiclone displays ~70% bioavailability due to first‑pass metabolism. Food intake moderately delays absorption for Z‑drugs but has minimal impact on barbiturates.

Distribution

High lipid solubility facilitates extensive CNS penetration. Protein binding ranges from 50–90% for barbiturates; Z‑drugs exhibit moderate binding (~30–50%). Distribution volumes approximate 0.5–0.8 L/kg for barbiturates and 0.6–1.0 L/kg for Z‑drugs, reflecting extensive tissue uptake.

Metabolism

Hepatic cytochrome P450 enzymes metabolize both classes. Phenobarbital induces CYP2B6 and CYP2C9, accelerating its own clearance and that of concomitant drugs. Z‑drugs are primarily metabolized by CYP3A4; eszopiclone undergoes conjugation via UGT2B7. Hepatic impairment prolongs half‑life, necessitating dose adjustment.

Excretion

Renal elimination accounts for 30–50% of barbiturate excretion; inactive metabolites are excreted unchanged. Z‑drugs are excreted mainly via the kidneys as conjugated metabolites; renal impairment can extend half‑life, especially for eszopiclone.

Half‑Life and Dosing

Phenobarbital: 24–48 h; secobarbital: 4–8 h; thiopental: <30 min (IV). Z‑drugs: zolpidem 2–3 h; zaleplon 1 h; eszopiclone 6–8 h. The short half‑life of Z‑drugs limits accumulation, whereas barbiturates require careful titration to avoid tolerance and dependence.

Therapeutic Uses / Clinical Applications

Barbiturates

• Seizure management: phenobarbital remains first‑line for neonatal seizures and refractory partial seizures.
• Pre‑anesthetic sedation: thiopental provides rapid induction for general anesthesia.
• Short‑term sleep aid: secobarbital occasionally prescribed for transient insomnia.

Z‑drugs

• Acute insomnia: zolpidem, zaleplon, and eszopiclone are indicated for sleep initiation and maintenance.
• Anxiety: zaleplon may be used for short‑term anxiolytic needs.
• Off‑label uses: Z‑drugs are sometimes employed for refractory agitation in intensive care settings and as adjuncts in palliative care to alleviate insomnia caused by pain or dyspnea.

Adverse Effects

Barbiturates

• Common: sedation, dizziness, ataxia, impaired coordination.
• Serious: respiratory depression, hypotension, hepatic toxicity, and dependence with chronic use.
• Black box warning: risk of respiratory depression and dependence; caution advised in patients with chronic pulmonary disease.

Z‑drugs

• Common: somnolence, headache, dysgeusia, transient memory impairment.
• Serious: paradoxical agitation, sleep‑walking, hallucinations, and rare respiratory depression, especially when combined with opioids or alcohol.
• Black box warning: potential for abuse and dependence; caution in patients with history of substance use disorder.

Drug Interactions

Barbiturates

• Inducers of CYP enzymes (e.g., rifampin, carbamazepine) reduce barbiturate plasma levels.
• Inhibitors (e.g., fluconazole, ketoconazole) increase levels, heightening risk of CNS depression.
• Concurrent use with opioids, benzodiazepines, or alcohol potentiates respiratory depression.

Z‑drugs

• CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) raise plasma concentrations, increasing adverse effect risk.
• Inhibitors of CYP2C19 (e.g., fluoxetine) may elevate eszopiclone levels.
• Co‑administration with opioids or alcohol enhances sedation and respiratory depression.

Contraindications include hypersensitivity to the drug or any excipient, severe hepatic impairment for barbiturates, and severe renal impairment for eszopiclone.

Special Considerations

Pregnancy / Lactation

Barbiturates cross the placenta and are excreted in breast milk; fetal exposure may lead to neonatal CNS depression. Z‑drugs are also placental permeable; limited data suggest potential neonatal sedation. Both classes are generally avoided unless benefits outweigh risks.

Pediatric / Geriatric Populations

Pediatric dosing requires careful titration; barbiturates can precipitate status epilepticus if abruptly discontinued. Geriatric patients are more susceptible to CNS depression; lower starting doses and slower titration are recommended.

Renal / Hepatic Impairment

Hepatic dysfunction prolongs barbiturate half‑life; dose reductions or alternative agents should be considered. Renal impairment extends Z‑drug half‑life, particularly eszopiclone; dose adjustments are warranted.

Summary / Key Points

• Barbiturates act as non‑competitive GABA agonists and sodium channel inhibitors; Z‑drugs are selective positive allosteric modulators of GABA_A receptors.
• Pharmacokinetic profiles differ markedly: barbiturates exhibit variable half‑lives and hepatic induction, whereas Z‑drugs possess rapid onset and limited accumulation.
• Barbiturates remain essential for refractory seizures and anesthesia, while Z‑drugs dominate acute insomnia therapy.
• Both classes carry risks of respiratory depression, dependence, and significant drug interactions, necessitating vigilant monitoring.
• Special populations require dose adjustments and careful risk‑benefit analysis, particularly in pregnancy, pediatrics, geriatrics, and hepatic or renal impairment.

References

1. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
2. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
3. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
4. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
7. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
8. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.